Advanced Diagnostic Breast Cancer Imaging: Variation and Patterns of Care in Washington State

Size: px
Start display at page:

Download "Advanced Diagnostic Breast Cancer Imaging: Variation and Patterns of Care in Washington State"

Transcription

1 Advanced Diagnostic Breast Cancer Imaging: Variation and Patterns of Care in Washington State Gold, et al Supplemental Tables 1 3 Supplemental Table 1. Breast biopsy codes, types, and descriptions. Code Type 1 Description CPT Biopsy of breast; percutaneous, needle core, not using imaging guidance (separate procedure) CPT Biopsy of breast; open, incisional CPT Biopsy of breast; percutaneous, needle core, using imaging guidance CPT Biopsy of breast; percutaneous, automated vacuum assisted or rotating biopsy device, using imaging guidance CPT Nipple exploration, with or without excision of a solitary lactiferous duct or a papilloma lactiferous duct CPT Excision of lactiferous duct fistula CPT Excision of cyst, fibroadenoma, or other benign or malignant tumor, aberrant breast tissue, duct lesion, nipple or areolar lesion (except 19300), open, male or female, 1 or more lesions CPT Excision of cyst, fibroadenoma, or other benign or malignant tumor, aberrant breast tissue, duct lesion, nipple, or areolar lesion (except 19300), open, male or female, 1 or more lesions CPT Excision of breast lesion identified by preoperative placement of radiological marker, open; single lesion CPT Excision of breast lesion identified by preoperative placement of radiological marker, open; each additional lesion separately identified by a preoperative radiological marker (List separately in addition to code for primary procedure) CPT Mastectomy, partial CPT Mastectomy, partial, with axillary lymphadenectomy CPT Mastectomy, simple, complete CPT Mastectomy, subcutaneous CPT Mastectomy, radical, including pectoral muscles, axillary lymph nodes CPT Mastectomy, radical, including pectoral muscles, axillary, and internal mammary lymph nodes CPT Mastectomy, modified radical, including axillary lymph nodes, with or without pectoralis minor muscle, but excluding pectoralis major muscle CPT Excision of chest wall tumor including ribs CPT Excision of chest wall tumor involving ribs, with plastic reconstruction; without mediastinal lymphadenectomy CPT Excision of chest wall tumor involving ribs, with plastic reconstruction; with mediastinal lymphadenectomy CPT Mastectomy, partial (eg, lumpectomy, tylectomy, quadrantectomy, segmentectomy) CPT Mastectomy, partial (eg, lumpectomy, tylectomy, quadrantectomy, segmentectomy); with axillary lymphadenectomy CPT Mastectomy, simple, complete CPT Mastectomy, subcutaneous CPT Mastectomy, radical, including pectoral muscles, axillary lymph nodes CPT Mastectomy, radical, including pectoral muscles, axillary and internal mammary lymph nodes (Urban type operation) CPT Mastectomy, radical, including pectoral muscles, axillary and internal mammary lymph nodes (Urban type operation) CPT Biopsy or excision of lymph node(s); open, superficial CPT Biopsy or excision of lymph node(s); by needle, superficial (eg, cervical, inguinal, axillary)

2 Code Type 1 Description CPT Biopsy or excision of lymph node(s); open, deep cervical node(s) CPT Biopsy or excision of lymph node(s); open, deep cervical node(s) with excision scalene fat pad CPT Biopsy or excision of lymph node(s); open, deep axillary node(s) CPT Biopsy or excision of lymph node(s); open, internal mammary node(s) ICD9 Biopsy of lymphatic structure ICD9 Excision of internal mammary lymph node ICD9 Excision of axillary lymph node 40.3 ICD9 Regional lymph node excision ICD9 Radical excision of axillary lymph nodes 85 ICD9 Mastotomy ICD9 Closed [percutaneous] [needle] biopsy of breast ICD9 Open biopsy of breast 85.2 ICD9 Excision or destruction of breast tissue, not otherwise specified ICD9 Local excision of lesion of breast ICD9 Resection of quadrant of breast ICD9 Subtotal mastectomy ICD9 Excision of ectopic breast tissue ICD9 Excision of nipple 85.3 ICD9 Reduction mammoplasty and subcutaneous mammectomy ICD9 Unilateral subcutaneous mammectomy with synchronous implant ICD9 Other unilateral subcutaneous mammectomy ICD9 Bilateral subcutaneous mammectomy with synchronous implant ICD9 Other bilateral subcutaneous mammectomy ICD9 Unilateral simple mastectomy ICD9 Bilateral simple mastectomy ICD9 Unilateral extended simple mastectomy ICD9 Bilateral extended simple mastectomy ICD9 Unilateral radical mastectomy ICD9 Bilateral radical mastectomy ICD9 Unilateral extended radical mastectomy ICD9 Bilateral extended radical mastectomy 257 DRG Mastectomy for malignancy with complications or co-morbidities (CC)/major complications or comorbidities (MCC) 258 DRG Mastectomy for malignancy without complications or co-morbidities (CC)/major complications or co-morbidities (MCC) 259 DRG Breast biopsy, local excision & other breast procedures with complications or co-morbidities (CC)/major complications or co-morbidities (MCC) 260 DRG Breast biopsy, local excision & other breast procedures without complications or co-morbidities (CC)/major complications or co-morbidities (MCC) 582 DRG Mastectomy for malignancy with complications or co-morbidities (CC)/major complications or comorbidities (MCC) 583 DRG Mastectomy for malignancy withour complications or co-morbidities (CC)/major complications or co-morbidities (MCC) 584 DRG Breast biopsy, local excision & other breast procedures with complications or co-morbidities (CC)/major complications or co-morbidities (MCC) 585 DRG Breast biopsy, local excision & other breast procedures without complications or co-morbidities (CC)/major complications or co-morbidities (MCC) 1 Abbreviations: CPT- Current Procedural Terminology; ICD9- International Classification of Diseases, 9 th Edition; DRG- Diagnosis Related Group

3 Supplemental Table 2. Treatment codes, types, and descriptions. SURGERY Code Type Description CPT Excision of cyst, fibroadenoma, or other benign or malignant tumor, aberrant breast tissue, duct lesion, nipple or areolar lesion (except 19300), open, male or female, 1 or more lesions CPT Excision of cyst, fibroadenoma, or other benign or malignant tumor, aberrant breast tissue, duct lesion, nipple, or areolar lesion (except 19300), open, male or female, 1 or more lesions CPT Excision of breast lesion identified by preoperative placement of radiological marker, open; single lesion CPT Excision of breast lesion identified by preoperative placement of radiological marker, open; each additional lesion separately identified by a preoperative radiological marker (List separately in addition to code for primary procedure) CPT Mastectomy, partial CPT Mastectomy, partial, with axillary lymphadenectomy CPT Mastectomy, partial (eg, lumpectomy, tylectomy, quadrantectomy, segmentectomy) Mastectomy, partial (eg, lumpectomy, tylectomy, quadrantectomy, segmentectomy); CPT with axillary lymphadenectomy ICD9 Other diagnostic procedures on breast 85.2 ICD9 Excision or destruction of breast tissue, not otherwise specified ICD9 Local excision of lesion of breast ICD9 Resection of quadrant of breast ICD9 Subtotal mastectomy ICD9 Excision of ectopic breast tissue ICD9 Excision of nipple 259 DRG Breast biopsy, local excision & other breast procedures w CC/MCC 260 DRG Breast biopsy, local excision & other breast procedures w/o CC/MCC 584 DRG BREAST BIOPSY, LOCAL EXCISION & OTHER BREAST PROCEDURES W CC/MCC BREAST BIOPSY, LOCAL EXCISION & OTHER BREAST PROCEDURES W/O CC/MCC 585 DRG CPT Mastectomy, simple, complete CPT Mastectomy, subcutaneous CPT Mastectomy, radical, including pectoral muscles, axillary lymph nodes CPT Mastectomy, radical, including pectoral muscles, axillary, and internal mammary lymph nodes Mastectomy, modified radical, including axillary lymph nodes, with or without pectoralis minor muscle, but excluding pectoralis major muscle CPT CPT Mastectomy, simple, complete CPT Mastectomy, subcutaneous CPT Mastectomy, radical, including pectoral muscles, axillary lymph nodes CPT Mastectomy, radical, including pectoral muscles, axillary and internal mammary lymph nodes (Urban type operation) Mastectomy, radical, including pectoral muscles, axillary and internal mammary lymph nodes (Urban type operation) CPT ICD9 Unilateral subcutaneous mammectomy with synchronous implant ICD9 Other unilateral subcutaneous mammectomy ICD9 Bilateral subcutaneous mammectomy with synchronous implant

4 85.36 ICD9 Other bilateral subcutaneous mammectomy ICD9 Unilateral simple mastectomy ICD9 Bilateral simple mastectomy ICD9 Unilateral extended simple mastectomy ICD9 Bilateral extended simple mastectomy ICD9 Unilateral radical mastectomy ICD9 Bilateral radical mastectomy ICD9 Unilateral extended radical mastectomy ICD9 Bilateral extended radical mastectomy 257 DRG Mastectomy for malignancy w CC/MCC 258 DRG Mastectomy for malignancy w/o CC/MCC 582 DRG MASTECTOMY FOR MALIGNANCY WITH CC 2 /MCC DRG MASTECTOMY FOR MALIGNANCY W/O CC/MCC CHEMOTHERAPY Code Type Description CPT Chemotherapy administration, subcutaneous or intramuscular; non-hormonal antineoplastic CPT Chemotherapy administration, subcutaneous or intramuscular; hormonal antineoplastic CPT Chemotherapy administration; intravenous, push technique, single or initial substance/drug CPT Chemotherapy administration; intravenous, push technique, each additional substance/drug (List separately in addition to code for primary procedure) CPT Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug CPT Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure) CPT Chemotherapy administration, intravenous infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours), requiring use of a portable or implantable pump CPT Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure) CPT Chemotherapy administration, intra-arterial; push technique CPT Chemotherapy administration, intra-arterial; infusion technique, up to 1 hour Chemotherapy administration, intra-arterial; infusion technique, each additional hour CPT (List separately in addition to code for primary procedure) Chemotherapy administration, intra-arterial; infusion technique, initiation of prolonged infusion (more than 8 hours), requiring the use of a portable or implantable pump CPT CPT Unlisted chemotherapy procedure C8953 HCPC Chemotherapy administration, intravenous; push technique C8954 HCPC Chemotherapy administration, intravenous; infusion technique, up to one hour Chemotherapy administration, intravenous; infusion technique, each additional hour (list separately in addition to c8954) C8955 HCPC C9414 HCPC Etoposide, oral, brand name, 50 mg C9415 HCPC Doxorubicin hcl, brand name, 10 mg C9417 HCPC Bleomycin sulfate, brand name, 15 units C9418 HCPC Cisplatin, powder or s0lution, brand name, per 10 mg C9419 HCPC Injection, cladribine, brand name, per 1 mg

5 C9420 HCPC Cyclophosphamide, brand name, 100 mg C9421 HCPC Cyclophosphamide, lyophilized, brand name, 100 mg C9422 HCPC Cytarabine, brand name, 100 mg C9423 HCPC Dacarbazine, brand name, 100 mg C9424 HCPC Daunorubicin, brand name, 10 mg C9425 HCPC Etoposide, brand name, 10 mg C9426 HCPC Floxuridine, brand name, 500 mg C9427 HCPC Ifosfamide, brand name, 1 gm C9428 HCPC Mesna, brand name, 200 mg C9429 HCPC Idarubicin hydrochloride, brand name, 5 mg C9430 HCPC Leuprolide acetate, brand name, per 1 mg C9431 HCPC Paclitaxel, brand name, 30 mg C9432 HCPC Mitomycin, brand name, 5 mg C9433 HCPC Thiotepa, brand name, 15 mg C9435 HCPC Injection, gonadorelin hydrochloride, brand name, per 100 mcg C9436 HCPC Azathioprine, parenteral, brand name, per 100 mg C9437 HCPC Carmustine, brand name, 100 mg G0353 HCPC Intravenous push, single or initial substance/drug G0355 HCPC Chemotherapy administration, subcutaneous or intramuscular non-hormonal antineoplastic G0356 HCPC Hormonal anti-neoplastic G0357 HCPC Intravenous, push technique, single or initial substance/drug G0358 HCPC Intravenous, push technique, each additional substance/drug (list separately in addition to code for primary procedure) G0359 HCPC Chemotherapy administration, intravenous infusion technique; up to one hour, single or initial substance/drug G0360 HCPC Each additional hour, one to eight (8) hours (list separately in addition to code for primary procedure) use g0360 in conjunction with g0359 G0361 HCPC Initiation of prolonged chemotherapy infusion (more than eight hours), requiring use of a portable or implantable pump Each additional sequential infusion (different substance/drug), up to one hour (use G0362 HCPC with g0359) Irrigation of implanted venous access device for drug delivery systems (do not report g0363 if an injection or infusion is provided on the same day) G0363 HCPC J1950 HCPC Injection, leuprolide acetate (for depot suspension), per 3.75 mg J3315 HCPC Injection, triptorelin pamoate, 3.75 mg J8510 HCPC Busulfan; oral, 2 mg J8520 HCPC Capecitabine, oral, 150 mg J8521 HCPC Capecitabine, oral, 500 mg J8530 HCPC Cyclophosphamide; oral, 25 mg J8540 HCPC Dexamethasone, oral, 0.25 mg J8560 HCPC Etoposide; oral, 50 mg J8597 HCPC Antiemetic drug, oral, not otherwise specified J8600 HCPC Melphalan; oral, 2 mg J8610 HCPC Methotrexate; oral, 2.5 mg J8650 HCPC Nabilone, oral, 1 mg J8700 HCPC Temozolomide, oral, 5 mg J8705 HCPC Topotecan, oral, 0.25 mg J8999 HCPC Prescription drug, oral, chemotherapeutic, nos

6 J9000 HCPC Injection, doxorubicin hydrochloride, 10 mg J9001 HCPC Injection, doxorubicin hydrochloride, all lipid formulations, 10 mg J9040 HCPC Injection, bleomycin sulfate, 15 units J9045 HCPC Injection, carboplatin, 50 mg J9050 HCPC Injection, carmustine, 100 mg J9060 HCPC Cisplatin, powder or solution, per 10 mg J9062 HCPC Cisplatin, 50 mg J9065 HCPC Injection, cladribine, per 1 mg J9070 HCPC Cyclophosphamide, 100 mg J9080 HCPC Cyclophosphamide, 200 mg J9091 HCPC Cyclophosphamide, 1.0 gram J9092 HCPC Cyclophosphamide, 2.0 gram J9093 HCPC Cyclophosphamide, lyophilized, 100 mg J9094 HCPC Cyclophosphamide, lyophilized, 200 mg J9095 HCPC Cyclophosphamide, lyophilized, 500 mg J9096 HCPC Cyclophosphamide, lyophilized, 1.0 gram J9097 HCPC Cyclophosphamide, lyophilized, 2.0 gram J9098 HCPC Injection, cytarabine liposome, 10 mg J9100 HCPC Injection, cytarabine, 100 mg J9110 HCPC Injection, cytarabine, 500 mg J9120 HCPC Injection, dactinomycin, 0.5 mg J9130 HCPC Dacarbazine, 100 mg J9140 HCPC Dacarbazine, 200 mg J9150 HCPC Injection, daunorubicin, 10 mg J9151 HCPC Injection, daunorubicin citrate, liposomal formulation, 10 mg J9165 HCPC Injection, diethylstilbestrol diphosphate, 250 mg J9170 HCPC Injection, docetaxel, 20 mg J9178 HCPC Injection, epirubicin hcl, 2 mg J9181 HCPC Injection, etoposide, 10 mg J9182 HCPC Etoposide, 100 mg J9190 HCPC Injection, fluorouracil, 500 mg J9200 HCPC Injection, floxuridine, 500 mg J9201 HCPC Injection, gemcitabine hydrochloride, 200 mg J9202 HCPC Goserelin acetate implant, per 3.6 mg J9206 HCPC Injection, irinotecan, 20 mg J9208 HCPC Injection, ifosfamide, 1 gram J9209 HCPC Injection, mesna, 200 mg J9211 HCPC Injection, idarubicin hydrochloride, 5 mg J9217 HCPC Leuprolide acetate (for depot suspension), 7.5 mg J9218 HCPC Leuprolide acetate, per 1 mg J9219 HCPC Leuprolide acetate implant, 65 mg J9245 HCPC Injection, melphalan hydrochloride, 50 mg J9250 HCPC Methotrexate sodium, 5 mg J9260 HCPC Methotrexate sodium, 50 mg J9263 HCPC Injection, oxaliplatin, 0.5 mg J9265 HCPC Injection, paclitaxel, 30 mg J9280 HCPC Mitomycin, 5 mg J9290 HCPC Mitomycin, 20 mg J9291 HCPC Mitomycin, 40 mg

7 J9293 HCPC Injection, mitoxantrone hydrochloride, per 5 mg J9310 HCPC Injection, rituximab, 100 mg J9320 HCPC Injection, streptozocin, 1 gram J9340 HCPC Injection, thiotepa, 15 mg J9350 HCPC Injection, topotecan, 4 mg J9355 HCPC Injection, trastuzumab, 10 mg J9357 HCPC Injection, valrubicin, intravesical, 200 mg J9360 HCPC Injection, vinblastine sulfate, 1 mg J9370 HCPC Vincristine sulfate, 1 mg J9375 HCPC Vincristine sulfate, 2 mg J9380 HCPC Vincristine sulfate, 5 mg J9390 HCPC Injection, vinorelbine tartrate, 10 mg J9395 HCPC Injection, fulvestrant, 25 mg J9600 HCPC Injection, porfimer sodium, 75 mg J9999 HCPC Not otherwise classified, antineoplastic drugs Q0083 HCPC Chemotherapy administration by other than infusion technique only (eg subcutaneous, intramuscular, push), per visit Q0084 HCPC Chemotherapy administration by infusion technique only, per visit Q0085 HCPC Chemotherapy administration by both infusion technique and other techique(s) (eg subcutaneous, intramuscular, push), per visit S0115 HCPC Bortezomib, 3.5 mg S0116 HCPC Bevacizumab, 100 mg S0156 HCPC Exemestane, 25 mg S0170 HCPC Anastrozole, oral, 1mg S0187 HCPC Tamoxifen citrate, oral, 10mg S9329 S9330 HCPC HCPC Home infusion therapy, chemotherapy infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code with s9330 or s9331) Home infusion therapy, continuous (twenty-four hours or more) chemotherapy infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem Home infusion therapy, intermittent (less than twenty-four hours) chemotherapy infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem S9331 HCPC ICD9 Injection or infusion of cancer chemotherapeutic substance V58.1 ICD9 Encounter for antineoplastic chemotherapy and immunotherapy V58.11 ICD9 Encounter for antineoplastic chemotherapy V58.12 ICD9 Encounter for immunotherapy for neoplastic condition V66.2 ICD9 Convalescence following chemotherapy V67.2 ICD9 Follow-up examination following chemotherapy NDC DIETHYLSTILBESTROL NDC DIETHYLSTILBESTROL NDC VINBLASTINE SULFATE NDC VINCRISTINE SULFATE NDC VINCRISTINE SULFATE NDC VINCRISTINE SULFATE

8 NDC VINCRISTINE SULFATE NDC VINCRISTINE SULFATE NDC VINCRISTINE SULFATE NDC VINCRISTINE SULFATE NDC VINCRISTINE SULFATE NDC GEMCITABINE HCL NDC GEMCITABINE HCL NDC PEMETREXED DISODIUM NDC PEMETREXED DISODIUM NDC DASATINIB NDC DASATINIB NDC DASATINIB NDC TESTOLACTONE NDC HYDROXYUREA NDC HYDROXYUREA NDC HYDROXYUREA NDC HYDROXYUREA NDC PROCARBAZINE HCL NDC ESTRAMUSTINE PHOSPHATE SODIUM NDC TRETINOIN NDC CAPECITABINE NDC CAPECITABINE NDC CAPECITABINE NDC CAPECITABINE NDC FLUOROURACIL NDC FLUOROURACIL NDC FLUOROURACIL NDC FLOXURIDINE NDC FLUOROURACIL NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC THIOTEPA NDC METHOTREXATE SODIUM NDC LEUCOVORIN CALCIUM NDC MITOXANTRONE HCL NDC MITOXANTRONE HCL

9 NDC MITOXANTRONE HCL NDC DACTINOMYCIN NDC TOSITUMOMAB NDC TOSITUMOMAB NDC TOSITUMOMAB IODINE NDC TOSITUMOMAB IODINE NDC TOPOTECAN HCL NDC TOPOTECAN HCL NDC NELARABINE NDC NELARABINE NDC TEMSIROLIMUS NDC TEMSIROLIMUS NDC DAUNORUBICIN HCL NDC DAUNORUBICIN HCL NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC CYTARABINE NDC CYTARABINE NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC STREPTOZOCIN NDC URACIL MUSTARD NDC CYTARABINE NDC CYTARABINE NDC CYTARABINE NDC CYTARABINE NDC MEDROXYPROGESTERONE ACET NDC EPIRUBICIN HCL NDC EPIRUBICIN HCL NDC TRIPTORELIN PAMOATE NDC TRIPTORELIN PAMOATE NDC TRIPTORELIN PAMOATE NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC IRINOTECAN HCL NDC IRINOTECAN HCL NDC EXEMESTANE NDC TRIPTORELIN PAMOATE NDC ESTRAMUSTINE PHOSPHATE SODIUM NDC DOXORUBICIN HCL

10 NDC DOXORUBICIN HCL NDC FLUOROURACIL NDC FLUOROURACIL NDC FLUOROURACIL NDC FLUOROURACIL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC BLEOMYCIN SULFATE NDC BLEOMYCIN SULFATE NDC IDARUBICIN HCL NDC IDARUBICIN HCL NDC IDARUBICIN HCL NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM/PF NDC IDARUBICIN HCL NDC IDARUBICIN HCL NDC IDARUBICIN HCL NDC IDARUBICIN HCL NDC IDARUBICIN HCL NDC IDARUBICIN HCL NDC IDARUBICIN HCL NDC IDARUBICIN HCL NDC IDARUBICIN HCL NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE

11 NDC CYCLOPHOSPHAMIDE NDC CYTARABINE NDC CYTARABINE NDC ETOPOSIDE NDC ETOPOSIDE NDC ETOPOSIDE NDC VINBLASTINE SULFATE NDC VINCRISTINE SULFATE NDC VINCRISTINE SULFATE NDC VINCRISTINE SULFATE NDC VINCRISTINE SULFATE NDC VINCRISTINE SULFATE NDC DEXRAZOXANE NDC DEXRAZOXANE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC MEGESTROL ACETATE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC IFOSFAMIDE NDC IFOSFAMIDE NDC IFOSFAMIDE NDC IFOSFAMIDE NDC IFOSFAMIDE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC IXABEPILONE NDC IXABEPILONE NDC MITOMYCIN NDC MITOMYCIN NDC MITOMYCIN NDC MITOMYCIN NDC METHOTREXATE SODIUM

12 NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC BLEOMYCIN SULFATE NDC BLEOMYCIN SULFATE NDC BLEOMYCIN SULFATE NDC CARMUSTINE NDC CARMUSTINE NDC CARMUSTINE NDC LOMUSTINE NDC LOMUSTINE NDC LOMUSTINE NDC LOMUSTINE NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC MITOMYCIN NDC ETOPOSIDE NDC ETOPOSIDE NDC ETOPOSIDE NDC ETOPOSIDE NDC BLEOMYCIN SULFATE NDC BLEOMYCIN SULFATE NDC TENIPOSIDE NDC TENIPOSIDE NDC MITOTANE NDC ETOPOSIDE NDC ETOPOSIDE NDC ETOPOSIDE NDC ETOPOSIDE NDC ETOPOSIDE NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CISPLATIN NDC CISPLATIN NDC CISPLATIN NDC CISPLATIN

13 NDC CISPLATIN NDC CISPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC ETOPOSIDE PHOSPHATE NDC PACLITAXEL,SEMI-SYNTHETIC NDC PACLITAXEL,SEMI-SYNTHETIC NDC PACLITAXEL,SEMI-SYNTHETIC NDC PACLITAXEL,SEMI-SYNTHETIC NDC PACLITAXEL,SEMI-SYNTHETIC NDC PACLITAXEL,SEMI-SYNTHETIC NDC PACLITAXEL,SEMI-SYNTHETIC NDC PACLITAXEL,SEMI-SYNTHETIC NDC PACLITAXEL,SEMI-SYNTHETIC NDC IFOSFAMIDE/MESNA NDC IFOSFAMIDE/MESNA NDC IFOSFAMIDE/MESNA NDC IFOSFAMIDE/MESNA NDC IFOSFAMIDE/MESNA NDC IFOSFAMIDE/MESNA NDC MESNA NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC ESTRAMUSTINE PHOSPHATE SODIUM NDC FLUOROURACIL NDC LEUPROLIDE ACETATE NDC OXALIPLATIN NDC OXALIPLATIN NDC OXALIPLATIN NDC OXALIPLATIN NDC OXALIPLATIN NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC DIETHYLSTILBESTROL DIPHOS NDC DACARBAZINE NDC DACARBAZINE NDC SORAFENIB TOSYLATE NDC LEUPROLIDE/LIDOCAINE HCL NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC MEGESTROL ACETATE

14 NDC MEDROXYPROGESTERONE ACET NDC HYDROXYUREA NDC MEGESTROL ACETATE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC MERCAPTOPURINE NDC MERCAPTOPURINE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC HYDROXYUREA NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC FLUOROURACIL NDC SUNITINIB MALATE NDC SUNITINIB MALATE NDC SUNITINIB MALATE NDC SUNITINIB MALATE NDC SUNITINIB MALATE NDC SUNITINIB MALATE NDC ETOPOSIDE NDC ETOPOSIDE NDC ETOPOSIDE

15 NDC PACLITAXEL,SEMI-SYNTHETIC NDC PACLITAXEL,SEMI-SYNTHETIC NDC PACLITAXEL,SEMI-SYNTHETIC NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC DAUNORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DACARBAZINE NDC DACARBAZINE NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC ETOPOSIDE NDC ETOPOSIDE NDC ETOPOSIDE NDC ETOPOSIDE NDC ETOPOSIDE NDC ETOPOSIDE NDC DOCETAXEL NDC DOCETAXEL NDC CARMUSTINE/POLIFEPROSAN NDC LETROZOLE NDC IMATINIB MESYLATE NDC IMATINIB MESYLATE NDC IMATINIB MESYLATE NDC IMATINIB MESYLATE NDC IMATINIB MESYLATE NDC NILOTINIB HYDROCHLORIDE NDC NILOTINIB HYDROCHLORIDE NDC MELPHALAN NDC MELPHALAN HCL NDC FLUOROURACIL NDC FLUOROURACIL NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC CHLORAMBUCIL NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC VINORELBINE TARTRATE NDC VINORELBINE TARTRATE NDC BUSULFAN NDC MERCAPTOPURINE NDC MERCAPTOPURINE NDC THIOGUANINE NDC DAUNORUBICIN HCL

16 NDC FLUTAMIDE NDC FLUTAMIDE NDC FLUTAMIDE NDC FLUTAMIDE NDC TOREMIFENE CITRATE NDC TOREMIFENE CITRATE NDC TEMOZOLOMIDE NDC TEMOZOLOMIDE NDC TEMOZOLOMIDE NDC TEMOZOLOMIDE NDC TEMOZOLOMIDE NDC TEMOZOLOMIDE NDC TEMOZOLOMIDE NDC TEMOZOLOMIDE NDC TEMOZOLOMIDE NDC TEMOZOLOMIDE NDC TEMOZOLOMIDE NDC TEMOZOLOMIDE NDC TEMOZOLOMIDE NDC TEMOZOLOMIDE NDC TEMOZOLOMIDE NDC TEMOZOLOMIDE NDC TEMOZOLOMIDE NDC TEMOZOLOMIDE NDC TEMOZOLOMIDE NDC TEMOZOLOMIDE NDC MEDROXYPROGESTERONE ACETATE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC NILUTAMIDE NDC NILUTAMIDE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE

17 NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC MEGESTROL ACETATE NDC MERCAPTOPURINE NDC FLUTAMIDE NDC FLUTAMIDE NDC MEGESTROL ACETATE NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC VINCRISTINE SULFATE NDC VINCRISTINE SULFATE NDC VINCRISTINE SULFATE NDC MEGESTROL ACETATE NDC PACLITAXEL,SEMI-SYNTHETIC NDC PACLITAXEL,SEMI-SYNTHETIC NDC PACLITAXEL,SEMI-SYNTHETIC NDC PACLITAXEL,SEMI-SYNTHETIC NDC PACLITAXEL,SEMI-SYNTHETIC NDC PACLITAXEL,SEMI-SYNTHETIC NDC PACLITAXEL,SEMI-SYNTHETIC NDC PACLITAXEL,SEMI-SYNTHETIC NDC FLUTAMIDE NDC FLUTAMIDE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC MELPHALAN NDC MELPHALAN HCL NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC CHLORAMBUCIL NDC LEUCOVORIN CALCIUM NDC VINORELBINE TARTRATE NDC VINORELBINE TARTRATE

18 NDC BUSULFAN NDC LAPATINIB DITOSYLATE NDC MERCAPTOPURINE NDC MERCAPTOPURINE NDC THIOGUANINE NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC FLUOROURACIL NDC LEUPROLIDE ACETATE NDC FLUTAMIDE NDC FLUTAMIDE NDC FLUTAMIDE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM/PF NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC ETOPOSIDE NDC DOXORUBICIN HCL NDC FLUOROURACIL NDC FLUOROURACIL NDC FLUOROURACIL NDC FLUOROURACIL NDC FLUOROURACIL NDC FLUOROURACIL NDC FLUOROURACIL/ADHESIVE BANDAGE NDC FLUOROURACIL NDC METHOTREXATE SODIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC METHOTREXATE SODIUM/PF

19 NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM/PF NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM NDC MITOXANTRONE HCL NDC MITOXANTRONE HCL NDC MITOXANTRONE HCL NDC ETOPOSIDE NDC ETOPOSIDE NDC ETOPOSIDE NDC ETOPOSIDE NDC STREPTOZOCIN NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC LEUCOVORIN CALCIUM NDC CYTARABINE NDC CYTARABINE NDC DACARBAZINE NDC DACARBAZINE NDC FLOXURIDINE NDC VINBLASTINE SULFATE NDC VINBLASTINE SULFATE

20 NDC VINCRISTINE SULFATE NDC VINCRISTINE SULFATE NDC VINCRISTINE SULFATE NDC ANASTROZOLE NDC ANASTROZOLE NDC ANASTROZOLE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC BICALUTAMIDE NDC BICALUTAMIDE NDC BICALUTAMIDE NDC FULVESTRANT NDC FULVESTRANT NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC GOSERELIN ACETATE NDC GOSERELIN ACETATE NDC GOSERELIN ACETATE NDC GOSERELIN ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC VINBLASTINE SULFATE NDC VINCRISTINE SULFATE NDC VINCRISTINE SULFATE NDC CYTARABINE NDC CYTARABINE NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC ETOPOSIDE NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC ETOPOSIDE NDC MERCAPTOPURINE NDC MERCAPTOPURINE

21 NDC VINBLASTINE SULFATE NDC VINCRISTINE SULFATE NDC VINCRISTINE SULFATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC LEUCOVORIN CALCIUM NDC METHOTREXATE SODIUM NDC VINBLASTINE SULFATE NDC VINCRISTINE SULFATE NDC VINCRISTINE SULFATE NDC VINCRISTINE SULFATE NDC FLUOROURACIL NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM NDC DACARBAZINE NDC DACARBAZINE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC DOXORUBICIN HCL NDC CYTARABINE NDC CYTARABINE NDC CYTARABINE NDC LEUCOVORIN CALCIUM NDC METHOTREXATE SODIUM NDC VINBLASTINE SULFATE NDC VINCRISTINE SULFATE NDC VINCRISTINE SULFATE NDC VINCRISTINE SULFATE NDC FLUOROURACIL NDC FLUOROURACIL NDC FLUOROURACIL NDC FLUOROURACIL NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM/PF

22 NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM NDC DACARBAZINE NDC DACARBAZINE NDC CYTARABINE NDC CYTARABINE NDC VINBLASTINE SULFATE NDC METHOTREXATE SODIUM NDC VINCRISTINE SULFATE NDC VINCRISTINE SULFATE NDC VINCRISTINE SULFATE NDC LEUCOVORIN CALCIUM NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC LEUCOVORIN CALCIUM NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEDROXYPROGESTERONE ACET NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET

23 NDC TRETINOIN NDC FLUTAMIDE NDC FLUTAMIDE NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC HYDROXYUREA NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC TAMOXIFEN CITRATE NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC MEGESTROL ACETATE NDC IRINOTECAN HCL NDC IRINOTECAN HCL NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC EPIRUBICIN HCL NDC EPIRUBICIN HCL NDC HYDROXYUREA NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC METHOTREXATE SODIUM NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET

24 NDC MEDROXYPROGESTERONE ACET NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC METHOTREXATE SODIUM NDC MEDROXYPROGESTERONE ACET NDC HYDROXYUREA NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC FLUOROURACIL NDC FLUOROURACIL NDC FLUOROURACIL NDC FLUOROURACIL NDC EPIRUBICIN HCL NDC EPIRUBICIN HCL NDC BLEOMYCIN SULFATE NDC BLEOMYCIN SULFATE NDC BLEOMYCIN SULFATE NDC BLEOMYCIN SULFATE NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC IFOSFAMIDE NDC IFOSFAMIDE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC LEUPROLIDE ACETATE NDC IFOSFAMIDE/MESNA NDC IFOSFAMIDE/MESNA NDC IFOSFAMIDE/MESNA NDC IFOSFAMIDE/MESNA

25 NDC IFOSFAMIDE/MESNA NDC IFOSFAMIDE/MESNA NDC IDARUBICIN HCL NDC IDARUBICIN HCL NDC IDARUBICIN HCL NDC IDARUBICIN HCL NDC IDARUBICIN HCL NDC IDARUBICIN HCL NDC VINORELBINE TARTRATE NDC VINORELBINE TARTRATE NDC VINORELBINE TARTRATE NDC VINORELBINE TARTRATE NDC VINORELBINE TARTRATE NDC VINORELBINE TARTRATE NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC THIOTEPA NDC THIOTEPA NDC VINCRISTINE SULFATE NDC VINCRISTINE SULFATE NDC IRINOTECAN HCL NDC IRINOTECAN HCL NDC STREPTOZOCIN NDC MITOXANTRONE HCL NDC MITOXANTRONE HCL NDC MITOXANTRONE HCL NDC MITOXANTRONE HCL NDC MITOXANTRONE HCL NDC MITOXANTRONE HCL NDC DAUNORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC DACARBAZINE NDC DACARBAZINE NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC CYTARABINE NDC CYTARABINE NDC CYTARABINE NDC CYTARABINE NDC DAUNORUBICIN HCL NDC DAUNORUBICIN HCL NDC DAUNORUBICIN HCL NDC ETOPOSIDE NDC ETOPOSIDE

26 NDC ETOPOSIDE NDC ETOPOSIDE NDC ETOPOSIDE NDC ETOPOSIDE NDC ETOPOSIDE NDC CISPLATIN NDC CISPLATIN NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC IRINOTECAN HCL NDC IRINOTECAN HCL NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC METHOTREXATE SODIUM NDC LEUCOVORIN CALCIUM NDC LEUCOVORIN CALCIUM NDC MEDROXYPROGESTERONE ACET

27 NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEGESTROL ACETATE NDC MEDROXYPROGESTERONE ACET NDC MEDROXYPROGESTERONE ACET NDC HYDROXYUREA NDC CISPLATIN NDC CISPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC DOXORUBICIN HCL NDC DOXORUBICIN HCL NDC IFOSFAMIDE NDC IFOSFAMIDE NDC IFOSFAMIDE NDC IFOSFAMIDE NDC ETOPOSIDE NDC ETOPOSIDE NDC IRINOTECAN HCL NDC IRINOTECAN HCL NDC IRINOTECAN HCL NDC IRINOTECAN HCL NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM NDC FLUOROURACIL NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC CYCLOPHOSPHAMIDE NDC VINORELBINE TARTRATE NDC VINORELBINE TARTRATE NDC CARBOPLATIN NDC CARBOPLATIN NDC CARBOPLATIN NDC EPIRUBICIN HCL NDC EPIRUBICIN HCL NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM/PF NDC METHOTREXATE SODIUM/PF

Hydration, IV Infusions, Injections and Vaccine Charge Process

Hydration, IV Infusions, Injections and Vaccine Charge Process There are a number of items to be considered when billing for the Nursing service to perform drug therapy, the charge process is divided into three specific groups of codes and processes. 1. Hydration

More information

Medications most likely to be seen in primary care

Medications most likely to be seen in primary care Hazardous Medicines The majority of medicines are not classed as hazardous. The only medicinal products that are automatically deemed to be hazardous are cytotoxic and cytostatic medicines. There is no

More information

GROUP 1 CARCINOGEN, CHEMOTHERAPY WASTE & OTHER HAZARDOUS DRUG DISPOSAL NAME APPROVAL DATE EFFECTIVE DATE REVISION RENEE MICHEL 05/01/11 0

GROUP 1 CARCINOGEN, CHEMOTHERAPY WASTE & OTHER HAZARDOUS DRUG DISPOSAL NAME APPROVAL DATE EFFECTIVE DATE REVISION RENEE MICHEL 05/01/11 0 GROUP 1 CARCINOGEN, CHEMOTHERAPY WASTE & OTHER HAZARDOUS DRUG DISPOSAL NAME APPROVAL DATE EFFECTIVE DATE REVISION RENEE MICHEL 05/01/11 0 INTRODUCTION Prior to commencing work involving carcinogens, chemotherapeutics

More information

Cost Differences in Cancer Care Across Settings

Cost Differences in Cancer Care Across Settings Cost Differences in Cancer Care Across Settings August 2013 THE MORAN COMPANY 1 Cost Differences in Cancer Care Across Settings In a prior memorandum, we presented evidence documenting the growing share

More information

THE HAZARDOUS WASTE (ENGLAND AND WALES) REGULATIONS 2005

THE HAZARDOUS WASTE (ENGLAND AND WALES) REGULATIONS 2005 THE HAZARDOUS WASTE (ENGLAND AND WALES) REGULATIONS 2005 Interim Guidance for the NHS Hospital Sector for England and Wales and Information for Scotland Additional paper copies may be requested by contacting:

More information

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted

More information

MASCC/ESMO Antiemetic Guideline 2013

MASCC/ESMO Antiemetic Guideline 2013 MASCC/ESMO Antiemetic Guideline 2013 Multinational Association of Supportive Care in Cancer Organizing and Overall Meeting Chairs: Richard J. Gralla, MD Fausto Roila, MD Maurizio Tonato, MD Jørn Herrstedt,

More information

Oncologic drug Exposure Risks and Prevention Guidelines 19 June 2014

Oncologic drug Exposure Risks and Prevention Guidelines 19 June 2014 Oncologic drug Exposure Risks and Prevention Guidelines 19 June 2014 ส งค กคามซ งอาจเป นอ นตรายต อส ขภาพ HAZARD? HAZARD ส งค กคามซ งอาจเป นอ นตรายต อส ขภาพ ENCLOSURE Substitution ส งค กคามซ งอาจเป นอ นตรายต

More information

for Extended Stability Parenteral Drugs Third Edition Caryn M. Bing, R.Ph., M.S., FASHP Editor

for Extended Stability Parenteral Drugs Third Edition Caryn M. Bing, R.Ph., M.S., FASHP Editor Extended Stability for Parenteral Drugs Third Edition Editor Caryn M. Bing, R.Ph., M.S., FASHP 1 American Society of Health-System Pharmacists Bethesda, Maryland Contents Preface Acknowledgments x/ Dedication

More information

BREAST CANCER - METASTATIC & LOCALLY ADVANCED CHEMOTHERAPY REGIMENS Capecitabine. Capecitabine + Docetaxel. Capecitabine + Vinorelbine

BREAST CANCER - METASTATIC & LOCALLY ADVANCED CHEMOTHERAPY REGIMENS Capecitabine. Capecitabine + Docetaxel. Capecitabine + Vinorelbine Capecitabine Capecitabine 1000-1250mg/m 2 oral TWICE daily for 14 days Until disease progression Capecitabine + Docetaxel Capecitabine 750-1000mg/m 2 oral TWICE daily for 14 days Up to 6 cycles Capecitabine

More information

MEDICAL CENTER ADMINISTRATIVE POLICY AND PROCEDURES SCOPE KFH Hospital, City Section No.

MEDICAL CENTER ADMINISTRATIVE POLICY AND PROCEDURES SCOPE KFH Hospital, City Section No. of 22 I. Purpose To establish safe medication practices for High Alert medications to maximize the safety of the medication processes associated with these medications. II. Policy. High alert medications

More information

MMA - 2005 Drug Administration Coding Revisions

MMA - 2005 Drug Administration Coding Revisions Related Change Request (CR) #: 3631 Related CR Release Date: December 10, 2004 Related CR Transmittal #: 129 Effective Date: January 1, 2005 Implementation Date: January 17, 2005 MMA - 2005 Drug Administration

More information

BREAST RECONSTRUCTION POST MASTECTOMY

BREAST RECONSTRUCTION POST MASTECTOMY BREAST RECONSTRUCTION POST MASTECTOMY CLINICAL POLICY Policy Number: SURGERY 095.11 T2 Effective Date: January 1, 2016 Table of Contents CONDITIONS OF COVERAGE... BENEFIT CONSIDERATIONS... COVERAGE RATIONALE...

More information

Preventing and Treating Nausea and Vomiting Caused by Cancer Treatment

Preventing and Treating Nausea and Vomiting Caused by Cancer Treatment A Patient s Guide Preventing and Treating Nausea and Vomiting Caused by Cancer Treatment Recommendations of the American Society of Clinical Oncology The American Society of Clinical Oncology (ASCO) is

More information

Breast Reconstruction Surgery

Breast Reconstruction Surgery Breast Reconstruction Surgery I. Policy University Health Alliance (UHA) will reimburse for Breast Reconstruction Surgery when it is determined to be medically necessary and when it meets the medical criteria

More information

Guidelines for the Management of. Nausea and Vomiting in Cancer Patients

Guidelines for the Management of. Nausea and Vomiting in Cancer Patients Guidelines for the Management of Nausea and Vomiting in Cancer Patients Guidelines for the Management of Nausea and Vomiting in Cancer Patients Management of chemotherapy-induced nausea and vomiting includes

More information

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History

More information

BREAST RECONSTRUCTION POST MASTECTOMY

BREAST RECONSTRUCTION POST MASTECTOMY COVERAGE DETERMINATION GUIDELINE BREAST RECONSTRUCTION POST MASTECTOMY Guideline Number: CDG.003.05 Effective Date: January 1, 2016 Table of Contents COVERAGE RATIONALE... DEFINITIONS... APPLICABLE CODES...

More information

Waste Management Policy

Waste Management Policy Sharepoint Location Non-clinical Policies and Guidelines Sharepoint Index Directory 3.0 Corporate Sub Area 3.2 Trustwide Management Key words (for search purposes) Waste, Hazardous, Sharps, Household Central

More information

PHARMACY 1000.519 Effective Date Title: 10/12 HIGH-ALERT / HIGH-RISK / HAZARDOUS / LOOK ALIKE / SOUND ALIKE MEDICATIONS. Michele Goeb-Burkett 10/12

PHARMACY 1000.519 Effective Date Title: 10/12 HIGH-ALERT / HIGH-RISK / HAZARDOUS / LOOK ALIKE / SOUND ALIKE MEDICATIONS. Michele Goeb-Burkett 10/12 XXX DAYTONA XXX _OCEANSIDE XXX HEALTH CARE PARTNERS POLICY & PROCEDURE Department: Policy Number PHARMACY 1000.519 Effective Date Title: 10/12 HIGH-ALERT / HIGH-RISK / HAZARDOUS / LOOK ALIKE / SOUND ALIKE

More information

Synagis (Palivizumab)

Synagis (Palivizumab) Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization

More information

FRIEND TO FRIEND CPT CODES 2015 2016. Diagnostic digital breast tomosynthesis, unilateral (list separately in addition to code for primary procedure)

FRIEND TO FRIEND CPT CODES 2015 2016. Diagnostic digital breast tomosynthesis, unilateral (list separately in addition to code for primary procedure) FRIEND TO FRIEND CPT CODES 2015 2016 CPT CODE SERVICE DESCRIPTION FEE EFFECTIVE G0101 Screening pelvic examination $36.69 01 Jan 16 G0202 Mammography, screening, digital, bilateral (2 view film study of

More information

Documentation Summary for Chemotherapy Administration, Nonchemotherapy Injections and Infusions

Documentation Summary for Chemotherapy Administration, Nonchemotherapy Injections and Infusions Documentation Summary for Chemotherapy Administration, Nonchemotherapy Injections and Infusions Documentation to Support Medical Necessity of Chemotherapy Services Date: April 23, 2012 Source Information:

More information

Chemotherapy Drugs: How They Work

Chemotherapy Drugs: How They Work Chemotherapy Drugs: How They Work Chemotherapy is the use of any drug (such as aspirin or penicillin) to treat any disease. But to most people, chemotherapy refers to drugs used for cancer treatment. It

More information

Effective Date: 6/3/14

Effective Date: 6/3/14 North Shore-Long Island Jewish Health System, Inc. Long Island Jewish Medical Center PATIENT CARE SERVICES POLICY TITLE: ORDERING, ADMINISTRATION AND DISPOSAL OF ORAL CHEMOTHERAPEUTIC AGENTS Prepared by:

More information

Analysis of Costs Associated With Administration of Intravenous Single-Drug Therapies in Metastatic Breast Cancer in a U.S.

Analysis of Costs Associated With Administration of Intravenous Single-Drug Therapies in Metastatic Breast Cancer in a U.S. RESEARCH Analysis of Associated With Administration of Intravenous Single-Drug Therapies Gregory B. Kruse, MPH, MSc; Mayur M. Amonkar, PhD; Gregory Smith, BA; Dean C. Skonieczny, MBA, BSE; and Spyros Stavrakas,

More information

Breast Cancer. Breast Cancer Page 1

Breast Cancer. Breast Cancer Page 1 Breast Cancer Summary Breast cancers which are detected early are curable by local treatments. The initial surgery will give the most information about the cancer; such as size or whether the glands (or

More information

ASWCS Policy for the Treatment of Extravasation Injury

ASWCS Policy for the Treatment of Extravasation Injury ASWCS Policy for the Treatment of Extravasation Injury Extravasation of Cytotoxic Drugs Introduction 1. The purpose of this policy is to inform practitioners of their responsibilities in relation to preventing

More information

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone

More information

SOUTH CENTRAL AMBULANCE SERVICE NHS FOUNDATION TRUST CORPORATE POLICY & PROCEDURE. No EPP20 WASTE MANAGEMENT. November 2015

SOUTH CENTRAL AMBULANCE SERVICE NHS FOUNDATION TRUST CORPORATE POLICY & PROCEDURE. No EPP20 WASTE MANAGEMENT. November 2015 SOUTH CENTRAL AMBULANCE SERVICE NHS FOUNDATION TRUST CORPORATE POLICY & PROCEDURE No EPP20 WASTE MANAGEMENT November 2015 DOCUMENT INFORMATION Author: Mike Kerrigan Head of Estates Consultation & Approval:

More information

NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010

NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010 NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Institute for Occupational

More information

Carcinoma of the vagina is a relatively uncommon disease, affecting only about 2,000 women in

Carcinoma of the vagina is a relatively uncommon disease, affecting only about 2,000 women in EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4 th Edition, 2001 Vagina Jeffrey L. Stern, MD Carcinoma of the vagina is

More information

Antiemetic Guidelines for Adult Patients Receiving Chemotherapy and Radiotherapy

Antiemetic Guidelines for Adult Patients Receiving Chemotherapy and Radiotherapy Antiemetic Guidelines f Adult Patients Receiving Chemotherapy and Radiotherapy Produced by Pinkie Chambers and Susanna Daniels University College Hospital NHS Foundation Trust November 2010 (Review date

More information

Chemotherapy Administration, Hydration and Therapeutic, Prophylactic, and Diagnostic Injections and Infusions

Chemotherapy Administration, Hydration and Therapeutic, Prophylactic, and Diagnostic Injections and Infusions Chemotherapy Administration, Hydration and Therapeutic, Prophylactic, and Diagnostic Injections and Infusions Table of Contents: Overview... Professional Services... 2 Services... 4 Overview Chemotherapy

More information

A guide to cancer types and chemotherapy medications

A guide to cancer types and chemotherapy medications A guide to cancer types and chemotherapy medications This guides lists words that mean cancer, cancer types and intravenous chemotherapy medications. If you have any questions, see page 10 for details

More information

Cancer Surgery Volume Study: ICD-9 and CPT Codes

Cancer Surgery Volume Study: ICD-9 and CPT Codes This paper contains the ICD-9 diagnostic and procedure codes and the CPT procedure codes used by researchers for a project of the California HealthCare Foundation (CHCF) and the California Office of Statewide

More information

Chapter 7: Lung Cancer

Chapter 7: Lung Cancer Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin

More information

Breast Cancer. Sometimes cells keep dividing and growing without normal controls, causing an abnormal growth called a tumor.

Breast Cancer. Sometimes cells keep dividing and growing without normal controls, causing an abnormal growth called a tumor. Breast Cancer Introduction Cancer of the breast is the most common form of cancer that affects women but is no longer the leading cause of cancer deaths. About 1 out of 8 women are diagnosed with breast

More information

Metastatic Breast Cancer - Pipeline Review, Q1 2011

Metastatic Breast Cancer - Pipeline Review, Q1 2011 Brochure More information from http://www.researchandmarkets.com/reports/1524592/ Metastatic Breast Cancer - Pipeline Review, Q1 2011 Description: Metastatic Breast Cancer - Pipeline Review, Q1 2011 Summary

More information

Objectives PREVENTION AND TREATMENT OF CINV & VTE IN ONCOLOGY PATIENTS. Case 1. Case 1. Case 2 2/1/2015

Objectives PREVENTION AND TREATMENT OF CINV & VTE IN ONCOLOGY PATIENTS. Case 1. Case 1. Case 2 2/1/2015 Objectives PREVENTION AND TREATMENT OF CINV & VTE IN ONCOLOGY PATIENTS Jennifer Gallanger, Pharm.D. Jennifer Kubert, Pharm.D. Pharmacy Practice Residents Providence Alaska Medical Center Discuss the pathophysiology

More information

Correct Coding for Infusions and Injections. Agenda. Supervision Levels. Regan Tyler, CPC, CPC-H, CPMA, CEMC, ACS-EM

Correct Coding for Infusions and Injections. Agenda. Supervision Levels. Regan Tyler, CPC, CPC-H, CPMA, CEMC, ACS-EM Correct Coding for Infusions and Injections Regan Tyler, CPC, CPC-H, CPMA, CEMC, ACS-EM 1 Agenda The hierarchy facility vs. clinic for infusion coding - Initial, each additional, each sequential, concurrent

More information

Provider Reimbursement for Women's Cancer Screening Program

Provider Reimbursement for Women's Cancer Screening Program Reimbursement Schedule July 1, 2015 June 30, 2016 Office Visits - Established Patients Office Visit / Minimal / no physician 99211 $ 16.70 Office Visit / Problem focused History / exam 99212 $ 36.46 Preventive

More information

Eliminating Infusion Confusion. Agenda

Eliminating Infusion Confusion. Agenda Eliminating Infusion Confusion (Drug Administrations in Facility and Non-facility Settings) Presented by Maria Rita Genovese, CPC, PCS & Maryann C. Palmeter, CPC, CENTC 1 Agenda Review of CPT codes What

More information

2004 Healthcare Common Procedure Coding System (HCPCS)

2004 Healthcare Common Procedure Coding System (HCPCS) Minnesota Health Care Programs (MHCP) Provider Update June 30, 2004 2004 Healthcare Common Procedure Coding System () This provider update informs providers of additions, changes and deletions to the national

More information

CHAPTER 2. Neoplasms (C00-D49) March 2014. 2014 MVP Health Care, Inc.

CHAPTER 2. Neoplasms (C00-D49) March 2014. 2014 MVP Health Care, Inc. Neoplasms (C00-D49) March 2014 2014 MVP Health Care, Inc. CHAPTER SPECIFIC CATEGORY CODE BLOCKS C00-C14 Malignant neoplasms of lip, oral cavity and pharynx C15-C26 Malignant neoplasms of digestive organs

More information

Fertility and Women With Cancer

Fertility and Women With Cancer Fertility and Women With Cancer Although not everyone ends up having children, most people want to at least have the option. Cancer and treatment for cancer can sometimes make this harder or even take

More information

Acute Lymphoblastic Leukaemia

Acute Lymphoblastic Leukaemia 1 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 Protocol Acute Lymphoblastic Leukaemia Acute Lymphoblastic Leukaemia and Lymphoblastic Lymphoma UKALL

More information

FREE ANSWER ONLINE FOR INSTANT RESULTS AT WWW.CANADIANHEALTHCARENETWORK.CA SEPTEMBER 2015. by Sanna Pellatt, BSc(Pharm) Learning objectives

FREE ANSWER ONLINE FOR INSTANT RESULTS AT WWW.CANADIANHEALTHCARENETWORK.CA SEPTEMBER 2015. by Sanna Pellatt, BSc(Pharm) Learning objectives FONT: HELVETICA NEUE 75 BOLD (MODIFIED) CYAN 50,YELLOW 100 MAGENTA 100 CYAN 100 Continuing Education THE NATIONAL CONTINUING EDUCATION PROGRAM FOR PHARMACY TECHNICIANS 1.25 CEUs FREE ANSWER ONLINE FOR

More information

Cytotoxic Therapy in Metastatic Breast Cancer

Cytotoxic Therapy in Metastatic Breast Cancer Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Version 2002: von Minckwitz Versions

More information

J_Code To NDC Billing Cross Reference Guide

J_Code To NDC Billing Cross Reference Guide J_Code To Billing Cross Reference Guide J0129 Injection, abatacept, 10 mg GENERIC J0129 UN 250 MG 250 MG 25 ABATACEPT/MALTOSE J0150 6 MG Injection adenosine 6 MG GENERIC J0150 ML 3 MG/ML 3 MG ML 1 0.5

More information

CHEMOTHERAPY PROTOCOLS V10.1

CHEMOTHERAPY PROTOCOLS V10.1 CHEMOTHERAPY PROTOCOLS V10.1 Issue Date: 10 th July 2014 Page 1 of 42 Filename: MCHACPROTO Issue No: 10.1 CCC Chemotherapy Protocols Haematological Malignancies... 3 Hodgkins disease...3 Non-Hodgkins Lymphoma...5

More information

Outpatient Billing/Coding: A Focus on Missed Reimbursement & Quality of Reported Data

Outpatient Billing/Coding: A Focus on Missed Reimbursement & Quality of Reported Data Outpatient Billing/Coding: A Focus on Missed Reimbursement & Quality of Reported Data 438 e wilson bridge road, suite 200 worthington, oh 43085-2382 888-779-5663 www.cleverleyassociates.com 1 All US Average

More information

What is breast cancer?

What is breast cancer? Breast Cancer What is breast cancer? Let us explain it to you. www.anticancerfund.org www.esmo.org ESMO/ACF Patient Guide Series based on the ESMO Clinical Practice Guidelines BREAST CANCER: A GUIDE FOR

More information

cure Cancer A Patient s Guide

cure Cancer A Patient s Guide A Patient s Guide tometastatic Breast Cancer Detection & Diagnosis Treatment Options Coping with Symptoms & Side Effects Living with Metastatic Breast Cancer Patient Perspective Questions Resources cure

More information

Basics of Systemic Anticancer Therapy Prescribing and Verification

Basics of Systemic Anticancer Therapy Prescribing and Verification CHAPTER 2 Basics of Systemic Anticancer Therapy Prescribing and Verification Trinh Pham Joan Rivington Learning Objectives Upon completion of the chapter, the reader will be able to: 1. Write clear and

More information

Novel Oral Anti-coagulants in Patients with Malignancy Lori-Ann Linkins, MD, MSc(Clin Epi), FRCPC McMaster University, Hamilton, ON

Novel Oral Anti-coagulants in Patients with Malignancy Lori-Ann Linkins, MD, MSc(Clin Epi), FRCPC McMaster University, Hamilton, ON Novel Oral Anti-coagulants in Patients with Malignancy Lori-Ann Linkins, MD, MSc(Clin Epi), FRCPC McMaster University, Hamilton, ON Disclosures Speaker honorarium from Bayer (rivaroxaban; Xarelto) and

More information

Breast cancer: Diagnosis and complex treatment. Ibolya Czegle MD PhD Semmelweis University 3rd Department of Internal Medicine

Breast cancer: Diagnosis and complex treatment. Ibolya Czegle MD PhD Semmelweis University 3rd Department of Internal Medicine Breast cancer: Diagnosis and complex treatment Ibolya Czegle MD PhD Semmelweis University 3rd Department of Internal Medicine Epidemiology Worldwide, breast cancer is the most frequently diagnosed life-threatening

More information

Small cell Lung cancer New Chemotherapy options. Nicolas Mach, MD,PD

Small cell Lung cancer New Chemotherapy options. Nicolas Mach, MD,PD Small cell Lung cancer New Chemotherapy options Nicolas Mach, MD,PD > 40 negative Phase III trials List of unsucessful drugs Pemetrexed, imatinib, bevacizumab, bcl-2 antagonist, ASCT, CASE PRESENTATION

More information

Breast Cancer Treatment Guidelines

Breast Cancer Treatment Guidelines Breast Cancer Treatment Guidelines DCIS Stage 0 TisN0M0 Tamoxifen for 5 years for patients with ER positive tumors treated with: -Breast conservative therapy (lumpectomy) and radiation therapy -Excision

More information

Hazards of Cytotoxic Drugs

Hazards of Cytotoxic Drugs 38 H Y G E I A HYGEIA Vol.1, No.1 March-Aug, 09 Hazards of Cytotoxic Drugs 1 2 Kiron SS, Saritha M 1 Academy of Pharmaceutical Sciences, Medical College, Pariyaram, Kannur, Kerala. 2 Crescent College of

More information

Avastin: Glossary of key terms

Avastin: Glossary of key terms Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.

More information

Male Health Issues. Survivorship Clinic

Male Health Issues. Survivorship Clinic Male Health Issues The effects of cancer therapy on male reproductive function depend on many factors, including the boy s age at the time of cancer therapy, the specific type and location of the cancer,

More information

Pediatric Oncology for Otolaryngologists

Pediatric Oncology for Otolaryngologists Pediatric Oncology for Otolaryngologists Frederick S. Huang, M.D. Division of Hematology/Oncology Department of Pediatrics The University of Texas Medical Branch Grand Rounds Presentation to Department

More information

Breast Cancer: from bedside and grossing room to diagnoses and beyond. Adriana Corben, M.D.

Breast Cancer: from bedside and grossing room to diagnoses and beyond. Adriana Corben, M.D. Breast Cancer: from bedside and grossing room to diagnoses and beyond Adriana Corben, M.D. About breast anatomy Breasts are special organs that develop in women during puberty when female hormones are

More information

2016 Hysterectomy Reimbursement Fact Sheet

2016 Hysterectomy Reimbursement Fact Sheet 2016 Hysterectomy Reimbursement Fact Sheet The information contained in this document is provided for informational purposes only and represents no statement, promise, or guarantee by Ethicon concerning

More information

Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015

Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015 Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015 Advanced Refractory Solid Tumors or Lymphomas ECOG-ACRIN EAY131 (NCI CIRB) Targeted Therapy Directed by Genetic Testing in Treating

More information

How Breast Cancer Treatment affects Massage Therapy

How Breast Cancer Treatment affects Massage Therapy How Breast Cancer Treatment affects Massage Therapy A Webinar with Tracy Walton, MS, LMT Part 4 of the More about Cancer Care and Massage Webinar Series 11 Background Tracy Walton Author Educator Researcher

More information

SMALL CELL LUNG CANCER

SMALL CELL LUNG CANCER Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New

More information

Re: Formal Request for NCD Reconsideration- Tumor Antigen by ImmunoassayCA125 (40-17)

Re: Formal Request for NCD Reconsideration- Tumor Antigen by ImmunoassayCA125 (40-17) May 9, 2005 Coverage and Analysis Group Centers for Medicare and Medicaid Services 7500 Security Blvd. (Mailstop C1-09-06) Baltimore, MD 21244 Re: Formal Request for NCD Reconsideration- Tumor Antigen

More information

Feline Lymphoma Chemotherapy and Chemotherapy Protocols

Feline Lymphoma Chemotherapy and Chemotherapy Protocols Feline Lymphoma Chemotherapy and Chemotherapy Protocols If you have reached this page, your cat probably has a definite diagnosis of feline lymphoma from your veterinarian. The information below is not

More information

Treating Recurrent Metastatic Breast Cancer

Treating Recurrent Metastatic Breast Cancer BREAST CANCER Treating Recurrent Metastatic Breast Cancer Presented by Julie Gralow, MD Fred Hutchinson Cancer Research Center Generosa Grana, MD UMDNJ/Robert Wood Johnson School of Medicine Patricia Spicer,

More information

BreastCancerTrials.org History Form: Completed Treatment for Breast Cancer ABOUT ME

BreastCancerTrials.org History Form: Completed Treatment for Breast Cancer ABOUT ME BreastCancerTrials.org History Form: Completed Treatment for Breast Cancer This form is for patients with DCIS or early stage invasive cancer who are: On hormone therapy after breast cancer surgery Or

More information

Cancer Care Quality Program. Treatment Pathways

Cancer Care Quality Program. Treatment Pathways Cancer Care Quality Program Treatment Pathways REVISED: UPDATES EFFECTIVE DECEMBER 1, 2015 1 TABLE OF CONTENTS Contents CANCER CARE QUALITY PROGRAM 3 BLADDER CANCER PATHWAYS 4 BREAST CANCER PATHWAYS 5

More information

Cancer and Fertility. Joanne Frankel Kelvin, MSN, RN, AOCN Clinical Nurse Specialist Memorial Sloan-Kettering Cancer Center

Cancer and Fertility. Joanne Frankel Kelvin, MSN, RN, AOCN Clinical Nurse Specialist Memorial Sloan-Kettering Cancer Center Cancer and Fertility Joanne Frankel Kelvin, MSN, RN, AOCN Clinical Nurse Specialist Memorial Sloan-Kettering Cancer Center Advances in cancer treatment have led to improvements in survival Survival rates

More information

An individual is considered an incident case only once per lifetime.

An individual is considered an incident case only once per lifetime. 1 DERM 4 MALIGNANT MELANOMA; SKIN Includes Invasive Malignant Melanoma Only; Does Not Include Secondary Melanoma; For Malignant Melanoma In-Situ, See Corresponding Case Definition Background This case

More information

Coding Companion for Radiology. A comprehensive illustrated guide to coding and reimbursement

Coding Companion for Radiology. A comprehensive illustrated guide to coding and reimbursement Coding Companion for Radiology A comprehensive illustrated guide to coding and reimbursement 2013 Contents Getting Started with Coding Companion...i Diagnostic Radiology Head/Neck...1 Chest...38 Spine/Pelvis...51

More information

Osteosarcoma: treatment beyond surgery

Osteosarcoma: treatment beyond surgery Osteosarcoma: treatment beyond surgery Eric Chow, DVM DACVS Sue Downing, DVM DACVIM-Oncology Providing the best quality care and service for the patient, the client, and the referring veterinarian. Osteosarcoma

More information

Extravasation guidelines 2007. Implementation Toolkit

Extravasation guidelines 2007. Implementation Toolkit Extravasation guidelines 2007 Guidelines Implementation Toolkit Contents Extravasation guidelines 2007 Introduction to the Extravasation guidelines Introduction 4 Overall Goal 4 Specific Targets and Aims

More information

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy

More information

Index of compounds with data indicating they either cross or do not cross the bbb (or are found in CSF).

Index of compounds with data indicating they either cross or do not cross the bbb (or are found in CSF). Index of compounds with data indicating they either cross or do not cross the bbb (or are found in CSF). As described in the preceding review, there are several important issues when considering a chemotherapeutic

More information

CMS Limitations Guide Mammograms and Bone Density Radiology Services

CMS Limitations Guide Mammograms and Bone Density Radiology Services CMS Limitations Guide Mammograms and Bone Density Radiology Services Starting July 1, 2008, CMS has placed numerous medical necessity limits on tests and procedures. This reference guide provides you with

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

Phase III trials in oncology

Phase III trials in oncology Phase III trials in oncology Setting standards of care? Siegfried Seeber and Ada H Braun* Survival data from phase III trials can be very misleading because patients are not offered the best follow-up

More information

BREAST CANCER WHAT HAPPENS AFTER SURGERY?

BREAST CANCER WHAT HAPPENS AFTER SURGERY? BREAST CANCER WHAT HAPPENS AFTER SURGERY? Contents: Planning further treatment Medical management of breast cancer Support and follow up Questions to ask your surgeon or oncologist Planning further treatment

More information

dedicated to curing BREAST CANCER

dedicated to curing BREAST CANCER dedicated to curing BREAST CANCER When you are diagnosed with breast cancer, you need a team of specialists who will share their knowledge of breast disease and the latest treatments available. At Cancer

More information

CHAPTER 6: TREATMENT FOR SMALL CELL LUNG CANCER

CHAPTER 6: TREATMENT FOR SMALL CELL LUNG CANCER CHAPTER 6: TREATMENT FOR SMALL CELL LUNG CANCER INTRODUCTION This chapter provides an overview of treatment for small cell lung cancer (SCLC). Treatment options are presented based on the extent of disease.

More information

Breast Cancer Treatment

Breast Cancer Treatment Breast Cancer Treatment Most women with breast cancer will have surgery. The two common types of surgery are breast-conserving surgery and mastectomy. Breast Conserving Surgery A lumpectomy removes only

More information

BreastCancerTrials.org History Form: Metastatic Breast Cancer ABOUT ME

BreastCancerTrials.org History Form: Metastatic Breast Cancer ABOUT ME BreastCancerTrials.org History Form: Metastatic Breast Cancer This form is for patients with metastatic breast cancer who were: Were recently diagnosed with metastatic breast cancer (cancer that has spread

More information

Male breast cancer - Wikipedia, the free encyclopedia

Male breast cancer - Wikipedia, the free encyclopedia pagina 1 van 5 Male breast cancer From Wikipedia, the free encyclopedia Male breast cancer is a relatively rare cancer in men that originates from the breast. As it presents a similar pathology as female

More information

Implications of dose rounding intravenous chemotherapy at a community based hospital

Implications of dose rounding intravenous chemotherapy at a community based hospital Implications of dose rounding intravenous chemotherapy at a community based hospital 1 2 ABSTRACT OBJECTIVES: To quantify and evaluate the total number of pharmacist interventions completed for dose rounding

More information

About chemotherapy for lung cancer

About chemotherapy for lung cancer About chemotherapy for lung cancer This information is about chemotherapy for lung cancer. There are sections on What is chemotherapy? Chemotherapy for small cell lung cancer Chemotherapy for non-small

More information

Locoregional & advanced esophagus or esophagogastric junction cancer

Locoregional & advanced esophagus or esophagogastric junction cancer Eloxatin (oxaliplatin) Prior Authorization Request (For Maryland Only) Send completed form to: Case Review Unit CVS/caremark Specialty Programs Fax: 866-249-6155 CVS/caremark administers the prescription

More information

Drugs covered under Medicare Part B or Part D

Drugs covered under Medicare Part B or Part D LABEL_NAME GENERIC_NAME MESSAGE GEMZAR INJ 1 GM GEMCITABINE HCL FOR INJ 1 GM ALIMTA INJ 500MG PEMETREXED DISODIUM FOR IV SOLN 500 MG (BASE EQUIV) FUNGIZONE INJ 50MG AMPHOTERICIN B FOR INJ 50 MG KYTRIL

More information

Coding Trends for Infusions and Injections. Injections

Coding Trends for Infusions and Injections. Injections Coding Trends for Infusions and Injections Lynn M. Anderanin, CPC,CPC I,COSC AHIMA Approved ICD 10 CM Trainer 1 Today s Agenda Infusions Injections Drugs 2 1 Infusions 3 categories of CPT codes for chemotherapy

More information

Early-stage Breast Cancer Treatment: A Patient and Doctor Dialogue

Early-stage Breast Cancer Treatment: A Patient and Doctor Dialogue page 1 Early-stage Breast Cancer Treatment: A Patient and Doctor Dialogue Q: What is breast cancer, and what type do I have? A: Cancer is a disease in which cells become abnormal and form more cells in

More information

Chemotherapy for pancreatic

Chemotherapy for pancreatic Chemotherapy for pancreatic cancer 1 Chemotherapy for pancreatic cancer This information is from the booklet Understanding pancreatic cancer. You may find the full booklet helpful. We can send you a free

More information

Questions and answers on breast cancer A guide for women and their physicians

Questions and answers on breast cancer A guide for women and their physicians Canadian Breast Cancer Initiative Questions and answers on breast cancer A guide for women and their physicians 2nd edition Based on The Canadian Clinical Practice Guidelines for the Care and Treatment

More information

GENERAL QUESTIONS FOR YOUR DOCTOR OR NURSE. 3. Can you refer me to a breast cancer support group or counselor?

GENERAL QUESTIONS FOR YOUR DOCTOR OR NURSE. 3. Can you refer me to a breast cancer support group or counselor? GENERAL QUESTIONS FOR YOUR DOCTOR OR NURSE 1. You can bring members of your family or a friend to talk to the doctor or nurse directly. 2. Where can I find more information about breast cancer? 3. Can

More information

Nicole Kounalakis, MD

Nicole Kounalakis, MD Breast Disease: Diagnosis and Management Nicole Kounalakis, MD Assistant Professor of Surgery Goal of Breast Evaluation The goal of breast evaluation is to classify findings as: normal physiologic variations

More information

Corporate Medical Policy Breast Surgeries

Corporate Medical Policy Breast Surgeries Corporate Medical Policy Breast Surgeries File Name: Origination: Last CAP Review: Next CAP Review: Last Review: breast_surgeries 1/2000 9/2015 9/2016 9/2015 Description of Procedure or Service Policy

More information